Skip to main content

Emgality Side Effects

Generic name: galcanezumab

Medically reviewed by Philip Thornton, DipPharm. Last updated on Dec 5, 2022.

Note: This document contains side effect information about galcanezumab. Some dosage forms listed on this page may not apply to the brand name Emgality.

Applies to galcanezumab: subcutaneous solution.

Serious side effects of Emgality

Along with its needed effects, galcanezumab (the active ingredient contained in Emgality) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking galcanezumab:

Incidence not known

  • Difficulty breathing
  • fast heartbeat
  • fever
  • hives, itching, skin rash
  • hoarseness
  • irritation
  • joint pain, stiffness, or swelling
  • redness of the skin
  • swelling of the eyelids, face, lips, hands, or feet
  • tightness in the chest
  • trouble with swallowing

Other side effects of Emgality

Some side effects of galcanezumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site

For Healthcare Professionals

Applies to galcanezumab: subcutaneous solution.


The most commonly reported adverse reaction has been injection site reactions.[Ref]


Frequency not reported: Hypersensitivity reactions (including dyspnea, urticaria, and rash)

Postmarketing reports: Anaphylaxis, angioedema[Ref]


Very common (10% or more): Anti-Drug-Antibodies (up to 12.5%)[Ref]


Very common (10% or more): Injection site reactions (18%)[Ref]

Injection site reaction included event terms such as injection site pain, injection site reaction, injection site erythema, and injection site pruritus.[Ref]


Common (1% to 10%): Vertigo


Common (1% to 10%): Pruritus

Uncommon (0.1% to 1%): Urticaria

Postmarketing reports: Rash


Common (1% to 10%): Constipation

Frequently asked questions


1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Cerner Multum, Inc. Australian Product Information.

3. Product Information. Emgality (galcanezumab). Lilly, Eli and Company. 2018.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.